Aripiprazol no tratamento do transtorno de estresse pós-traumático: um ensaio clínico aberto
| Autor: | Aline Ferri Schoedl, Jose Paulo Fiks, Marcelo Feijó de Mello, Mariana Cadrobbi Pupo Costa |
|---|---|
| Přispěvatelé: | Universidade Federal de São Paulo (UNIFESP) |
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Tratamento Patients Beck Anxiety Inventory Population Aripiprazole Quinolones Piperazines Ensaios clínicos controlados aleatórios law.invention Stress Disorders Post-Traumatic Randomized controlled trial law Internal medicine medicine Humans education Psychiatric Status Rating Scales education.field_of_study Transtornos de estresse pós-traumáticos Beck Depression Inventory Traumatic stress Repeated measures design Stress disorders Treatment Psychiatry and Mental health Treatment Outcome Aripiprazol Female Pacientes Open label Psychology post-traumatic Antipsychotic Agents medicine.drug Clinical psychology |
| Zdroj: | Revista Brasileira de Psiquiatria, Volume: 30, Issue: 4, Pages: 358-361, Published: DEC 2008 Repositório Institucional da UNIFESP Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP Brazilian Journal of Psychiatry v.30 n.4 2008 Brazilian Journal of Psychiatry (São Paulo. 1999. Online) Associação Brasileira de Psiquiatria (ABP) instacron:ABP |
| Popis: | OBJETIVO: O transtorno de estresse pós-traumático é um quadro prevalente (7,8%-lifetime-EUA) que provoca grande prejuízo aos pacientes. Os inibidores seletivos de recaptação de serotonina, medicação de primeira escolha para o tratamento, mostram baixos índices de remissão. Este estudo pretende apresentar uma diferente escolha de medicamento para tratar o transtorno de estresse pós-traumático. MÉTODO: Trinta e dois pacientes com transtorno de estresse pós-traumático receberam aripiprazol por 16 semanas. Foram submetidos na entrada, 8 e 16 semanas às escalas Clinician-Administered PTSD Scale, Beck Depression Inventory, Beck Anxiety Inventory, Medical Outcome Study Short Form 36 e Social Adjustment Scale. Foi usado o modelo linear generalizado para medidas repetidas comparando o fator com as três medidas contínuas nos três pontos de avaliação. Foi feita uma comparação entre sujeitos (grupo tratamento) usando modelo linear generalizado univariado. Usamos a intenção de tratamento e a estratégia da última observação com endpoint (Last Observation Carried Forward). RESULTADOS: Nove pacientes descontinuaram antes da segunda avaliação. A dose média foi 9,6 (± 4,3) mg/dia. As medidas na entrada e no final do tratamento foram: Clinician-Administered PTSD Scale - 82,7 (± 23,1) e 51,4 (± 31,4) (F = 11,247, p = 0,001); Beck Anxiety Inventory - 31,7 (± 13,4) e 25,4 (± 18,2) (F = 8,931, p = 0,011); Social Adjustment Scale - 2,4 (± 0,45) e 2,27 (± 0,57) (F = 8,633, p = 0,012); Medical Outcome Study Short Form 36 - 76,6 (± 14,11) e 94,01 (± 25,06) (F = 10,127 p = 0,007); e Beck Depression Inventory - 26,06 (± 11,6) e 21,35 (± 12,6) (F = 1,580, p = 0,042). Em todas as medidas, as diferenças foram estatisticamente significativas. CONCLUSÕES: O aripiprazol alcançou uma boa resposta em pacientes com transtorno de estresse pós-traumático, mas para resultados mais acurados ainda são necessários estudos controlados com placebo. OBJECTIVE: Post traumatic stress disorder is frequent in the general population (7.8%-lifetime-USA). The selective serotonin reuptake inhibitors are the first choice of treatment but result in low remission rates. This study aims to evaluate the effect of aripiprazole monotherapy for the treatment of post traumatic stress disorder. METHOD: Thirty-two patients diagnosed with post traumatic stress disorder were included in a 16-week open label trial of aripiprazole. They were evaluated at baseline, week 8, and 16 with the Clinician-Administered PTSD Scale, Beck Depression Inventory, Beck Anxiety Inventory, Medical Outcome Study Short Form 36, and Social Adjustment Scale. Statistical analysis were performed with an intention-to-treat approach and last observation carried forward. A general linear model for repeated measures comparing the factor with 3 continuous measures from baseline, 8 and 16 weeks was used. A between-subject factor was included RESULTS: Nine patients discontinued the treatment. The mean aripiprazole dose was 9.6 (± 4.3) mg/day. The mean scores at baseline and endpoint for all measures were: Clinician-Administered PTSD Scale - 82.7 (± 23.1) and 51.4 (± 31.4) (F = 11.247, p = 0.001); Beck Anxiety Inventory - 31.7 (± 13.4) and 25.4 (± 18.2) (F = 8.931, p = 0.011); Social Adjustment Scale - 2.4 (± 0.45) and 2.27 (± 0.57) (F = 8.633, p = 0.012); Medical Outcome Study Short Form 36 - 76.6 (± 14.11) and 94.01 (± 25.06) (F = 10.127 p = 0.007); and Beck Depression Inventory - 26.06 (± 11.6) and 21.35 (± 12.6) (F = 1.580, p = 0.042). In all measurements, the differences were statistically significant. CONCLUSIONS: Patients achieved a good response to treatment with aripiprazole, but placebo-controlled studies are needed for more accurate results. Universidade Federal de São Paulo (UNIFESP) Department of Psychiatry Victims of Violence and Stress Program UNIFESP, Department of Psychiatry Victims of Violence and Stress Program SciELO |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|